Expression of hormone receptor (HR) and HER2 in tumor specimens from 1169 patients was centrally determined by immunohistochemistry and fluorescence in situ; breast cancer was classified into HR+/HER2−, HR+/HER2+, triple-negative, and HER2+ subtypes. This evidence concerns the gene NR4A1 and breast cancer.